Literature DB >> 34447194

Assessment of C-Reactive Protein Level in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma Patient.

Geeta Sharma1, Randhir Kumar2, Sharib Abdus Salam2, Prashant Bhasin3, Nishant Kumar Tewari4, Suman Yadav5.   

Abstract

BACKGROUND: Potentially malignant disorders are highly prevalent in India. In this study, we assessed C-reactive protein (CRP) levels in patients with oral submucous fibrosis (OSMF) and oral squamous cell carcinoma (OSCC).
METHODOLOGY: Sixty-four patients (OSMF and OSCC) were undertaken and were classified into 3 groups, OSMF patients (Group I, 34), OSCC (Group II, 30), and healthy controls (Group III, 26). Immunoturbidimetry method was used for the estimation of CRP levels.
RESULTS: Maximum cases in Group I was seen in the age group 40-60 years (males-10, females-3), Group II in the age group 40-60 years (males-11, females-5) and Group III (males-5, females-6). The mean CRP level in Group I was 6.12 ± 4.5 mg/l, in Group II was 28.4 ± 21.5 mg/l, and in Group III was 3.15 ± 2.19 mg/l. The difference was significant (P < 0.05).
CONCLUSION: Authors found that OSMF and oral cancer patients had increased CRP levels as compared to healthy subjects. Copyright:
© 2021 Journal of Pharmacy and Bioallied Sciences.

Entities:  

Keywords:  C-reactive protein; immunoturbidimetry; oral squamous cell carcinoma; oral submucous fibrosis

Year:  2021        PMID: 34447194      PMCID: PMC8375920          DOI: 10.4103/jpbs.JPBS_607_20

Source DB:  PubMed          Journal:  J Pharm Bioallied Sci        ISSN: 0975-7406


INTRODUCTION

Potentially malignant disorders (PMDs) are highly prevalent in India. The high consumption of areca nut and tobacco among South Indians raises the alarm to control its use.[1] Nowadays, the cases of oral submucous fibrosis (OSMF) and oral cancer are increasing among females. Earlier, there had been a high prevalence of PMDs among males due to the rapid use of tobacco and their products. However, in the last few years, consumption among females has enhanced due to many reasons.[2] OSMF leads to stiffness of mucosa and difficult mouth opening due to the formation of collagen bands in the buccal mucosa, labial mucosa, soft palate, etc. OSMF is associated with malignant transformation if timely intervention is not performed. Prompt identification and prevention of these PMDs may decrease the incidence and subsequently help in achieving better survival of patients who develop oral squamous cell carcinoma (OSCC).[3] Oral cancer accounts significantly for head and neck region cancer. The incidence was found to be 300,000 universally. It is the foremost reason of deaths. It has <50% survival rate in 5 years. C-reactive protein (CRP), fibrinogen, and serum amyloid A protein are few examples of acute-phase proteins whose values alter in the presence of inflammation. CRP found to show an elevated level in malignancy is considered to be a prognostic factor.[4] Various inflammatory cytokines like interleukin (IL)-1 and IL-6 etc., encourage the production of CRP by hepatocytes. Tumor necrosis factor-α also contribute significantly. Studies have been done in the past showing alteration in CRP level in patients with PMDs.[5] Considering this, we attempted to assess CRP level in OSMF and OSCC patients.

METHODOLOGY

We recruited 64 cases of OSMF and OSCC disorders of both genders reported to the Department of Oral Medicine and Radiology. The diagnosis of PMDs and OSCC was made clinically as well as histopathologically. We included 26 healthy subjects as control. Ethical approval for the study was taken before starting it, followed by written consent in vernacular language from all subjects. The demographic profile of all subjects was recorded in case history pro forma. Patients were divided into three groups. Group I comprised OSMF patients (34), group II had cases of OSCC (30), and Group III had healthy controls (26). All patients underwent collection of 2-ml venous blood samples using the standard venipuncture technique. Serum from blood was separated with centrifugation technique. Immunoturbidimetry method was used for the estimation of CRP levels. Results of the study were entered in MS excel sheet for statistical inference using Statistical Package of Social Sciences (SPSS) version 21 (IBM, Armonk, NY, USA). Data were expressed as mean ± standard deviation, maximum and minimum values using Kruskal–Wallis test and analysis of variance. 0.05 value was set as significance.

RESULTS

Table 1 shows distribution of subjects in different groups.
Table 1

Distribution of subjects

GroupsGroup IGroup IIGroup III
StatusOSMFOSCCControl
n 343026

OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma

Distribution of subjects OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma Table 2 shows that maximum cases in Group I was seen in the age group 40–60 years (males-10, females-3), Group II in the age group 40–60 years (males-11, females-5), and Group III (males-5, females-6).
Table 2

Age-wise distribution

Age group (years) Group I (34)Group II (30)Group III (26)



MaleFemaleMaleFemaleMaleFemale
20-40786455
40-6010311556
>60513132
Total221220101313
Age-wise distribution Table 3 and Graph 1 shows that the mean CRP level in Group I was 6.12 ± 4.5 mg/l, in Group II was 28.4 ± 21.5 mg/l, and in Group III was 3.15 ± 2.19 mg/l. The difference was significant (P < 0.05).
Table 3

Assessment of C-reactive protein in all groups

GroupsMeanSDMaximumMinimum P
Group I6.124.51.58.40.01
Group II28.421.511.337.2
Group III3.152.190.86.3

SD: Standard deviation

Graph 1

Assessment of C-reactive protein in all groups

Assessment of C-reactive protein in all groups SD: Standard deviation Assessment of C-reactive protein in all groups

DISCUSSION

Tobacco is the leading cause of PMDs and OSCC. Tobacco is consumed as smoking form and smokeless form.[6] Various forms of smoking tobacco is cigarette, bidi, hookah, hookli, etc. Smokeless form of tobacco comprised of chaini khaini, zarda, pan masala, mawa, mishri, etc. Tobacco contains carcinogen products polycyclic hydrocarbon, nitrosamine, etc.[7] The onset of OSMF is sudden. Patients experience multiple symptoms for which they report to the dental surgeon. The foremost complaint of the patients is the burning sensation on eating spicy and hot beverages. With the passage of time, multiple blisters and ulceration start appearing on the palate. Recurrent stomatitis and excessive salivation occur within few days, and ultimately xerostomia occurs.[8] The composition of areca nut is arecoline, arecadine, guvacoline, guvacine, and isoguvacine. Research reveals that there is nitrosation of arecoline with use resulting in the formation of arecanut specific nitrasamine.[9] These compounds are potential carcinogens and cause alkylation of. In this study, we assessed CRP level in OSMF and OSCC patients. We found that there were 34 cases of OSMF, 30 cases of OSCC, and 26 controls. Age group 20–40 years had 7 males and 8 females in Group I, 6 males and 4 females in Group II, and 5 males and 5 females in Group III, Age group 40–60 years had 10 males and 3 females, Group II had 11 males and 5 females in Group II, and 5 males and 6 females in Group III. Age >60 comprised of 5 males and 1 female in Group I, 3 males and 1 female in Group II and 3 males and 2 females. Vankadara et al.[10] recruited 30 healthy controls (Group I), while Group II had 30 patients of leukoplakia, OSMF and OLP and Group III had 30 cases of squamous cell carcinoma. The result showed that mean CRP levels in Group I was 3.88 ± 4.50 mg/l with range from 0.1 to 18.3 mg/l. In Group II, mean CRP level was 5.59 ± 9.86 mg/l with rang from 0.8 to 53.9 mg/l. In Group III, mean CRP level was 31.72 ± 31.01 mg/l, which rang from 3.3 to 96 mg/l. We found that mean CRP level in Group I was 6.12 ± 4.5 mg/l, in Group II was 28.4 ± 21.5 mg/l and in Group III was 3.15 ± 2.19 mg/l. Gosavi and Torkadi[11] conducted a study with 50 healthy, 50 OSMF and 50 OSCC individuals who were divided into Group I, Group II and Group III, respectively. The mean value of serum CRP in Group I was 2.20 ± 1.74 mg/L; in Group II, it was 5.40 ± 4.79 mg/L and in Group III, it was 12.17 ± 11.38 mg/L. Kaja et al.[12] consisted of 20 cases of oral PMDs (Leukoplakia-10, Oral Sub mucous fibrosis-10). Mean CRP levels in leukoplakia was 0.33 ± 0.17, in OSMF was 0.58 ± 0.83 where as in controls it was 0.26 ± 0.05. In PMDs, CRP was slightly elevated when compared with the controls. It is mentioned in the literature that CRP level increases significantly in tissue in active phase of disease and in cancer patients. It is a receptive marker of inflammation. It is evident stimulation by IL-6 significantly CRP levels in the liver and additional organs. CRP can be increased by both acute and chronic stimulation.[13] It is a defensive mechanism against viral and bacterial infections. Elevation of CRP has also been seen in connective tissue diseases, cardiovascular diseases, infections, inflammatory conditions, tuberculosis, rheumatoid arthritis, and women using oral contraceptives.[14] Anand Kumar and Bhateja[15] also observed that the level of serum CRP level was significantly higher in OSMF cases in comparison to the control group. The shortcoming of the study is the small sample size.

CONCLUSION

The authors found that OSMF and oral cancer patients had increased CRP level as compared to healthy subjects.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  11 in total

Review 1.  Oral submucous fibrosis: review on aetiology and pathogenesis.

Authors:  W M Tilakaratne; M F Klinikowski; Takashi Saku; T J Peters; Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2005-11-28       Impact factor: 5.337

2.  Prevalence of oral lesions in relation to habits: Cross-sectional study in South India.

Authors:  T R Saraswathi; K Ranganathan; S Shanmugam; Ramesh Sowmya; Prem Deepa Narasimhan; R Gunaseelan
Journal:  Indian J Dent Res       Date:  2006 Jul-Sep

3.  Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.

Authors:  Ines Gockel; Kathrin Dirksen; Claudia-M Messow; Theodor Junginger
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.

Authors:  Kristine H Allin; Stig E Bojesen; Børge G Nordestgaard
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

Review 5.  Oral cancer and precancerous lesions.

Authors:  Brad W Neville; Terry A Day
Journal:  CA Cancer J Clin       Date:  2002 Jul-Aug       Impact factor: 508.702

6.  Altered serum and salivary C-reactive protein levels in patients with oral premalignant lesions and oral squamous cell carcinoma.

Authors:  R Metgud; S Bajaj
Journal:  Biotech Histochem       Date:  2015-11-03       Impact factor: 1.718

7.  Serum C-reactive protein in oral submucous fibrosis and oral squamous cell carcinoma: A cross-sectional study.

Authors:  Suchitra Rajesh Gosavi; Amruta Appasaheb Torkadi
Journal:  J Oral Maxillofac Pathol       Date:  2020-05-08

8.  Evaluation of Serum C-Reactive Protein Levels in Oral Premalignancies and Malignancies: A Comparative Study.

Authors:  Sairam Vankadara; Padmaja K; Praveen Kumar Balmuri; Naresh G; Vikas Reddy G
Journal:  J Dent (Tehran)       Date:  2018-11

9.  Relationship of inflammatory markers and pain in patients with head and neck cancer prior to anticancer therapy.

Authors:  K G Oliveira; S V von Zeidler; A Z Lamas; J R V de Podestá; A Sena; E D Souza; J Lenzi; E M Lemos; S A Gouvea; N S Bissoli
Journal:  Braz J Med Biol Res       Date:  2014-05-30       Impact factor: 2.590

10.  Smokeless tobacco consumption impedes metabolic, cellular, apoptotic and systemic stress pattern: A study on Government employees in Kolkata, India.

Authors:  Sushobhan Biswas; Krishnendu Manna; Ujjal Das; Amitava Khan; Anirban Pradhan; Aaveri Sengupta; Surajit Bose; Saurabh Ghosh; Sanjit Dey
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.